|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 10, 2016 ) Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.
Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 2, 23, 12, 2, 74, 25 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 42 and 9 molecules, respectively.Amyotrophic Lateral Sclerosis.
Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/amyotrophic-lateral-sclerosis-pipeline-review-h2-2016
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001492648/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Companies profiles
2-BBB Medicines BV
AB Science SA
Aestus Therapeutics Inc
Anavex Life Sciences Corp
Angion Biomedica Corp
Apodemus AB
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001492648/discount
List of Tables
Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2016 29
Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H2 2016 30
Number of Products under Development by Companies, H2 2016 32
Number of Products under Development by Companies, H2 2016 (Contd..1) 33
Number of Products under Development by Companies, H2 2016 (Contd..2) 34
Number of Products under Development by Companies, H2 2016 (Contd..3) 35
Number of Products under Development by Companies, H2 2016 (Contd..4) 36
Number of Products under Development by Companies, H2 2016 (Contd..5) 37
Number of Products under Development by Companies, H2 2016 (Contd..6) 38
Number of Products under Development by Companies, H2 2016 (Contd..7) 39
List of Figures
Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2016 29
Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H2 2016 30
Number of Products under Development by Companies, H2 2016 31
Number of Products under Investigation by Universities/Institutes, H2 2016 40
Comparative Analysis by Late Stage Development, H2 2016 42
Comparative Analysis by Clinical Stage Development, H2 2016 43
Comparative Analysis by Early Stage Products, H2 2016 44
Assessment by Monotherapy Products, H2 2016 148
Assessment by Combination Products, H2 2016 149
Assessment by Monotherapy Products, H2 2016 149
Number of Products by Top 10 Targets, H2 2016 151
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
